New appointment aimed at enhancing commercial growth of eProtein Discovery while supporting strategic development.
CAMBRIDGE, England, February 24, 2025–(BUSINESS WIRE)–Nuclera, a biotechnology firm that accelerates protein expression and optimization using its benchtop eProtein Discovery™ system, has announced the appointment of Seth Benson as Chief Financial Officer. He will join CEO Dr. Michael Chen in the executive team to drive commercial and strategic initiatives, generate revenue, and facilitate business expansion post the Company’s USD $75 million financing completion1.
Seth’s recruitment follows the strengthening of Nuclera’s leadership with three pivotal appointments2, as the Company enters the next phase of its commercial development. With his extensive experience in establishing financial and operational frameworks, Seth is expected to be a key player in steering Nuclera’s upcoming commercial growth in major global markets.
Bringing over 20 years of leadership in finance, strategy, and operations primarily in the life sciences and healthcare sectors, Seth has a strong history of scaling operations, driving strategic growth, streamlining processes, and leading financial strategies. He has successfully spearheaded fundraising efforts, acquisitions, restructurings, and IPOs, notably at Akoya Biosciences, where he helped scale the workforce to over 300 and played a crucial role in the company’s IPO.
Prior to this, Seth was CFO at Vizgen, a company focused on enhancing human health through spatial genomics, where he oversaw finance, operations, and IT and guided the company through its acquisition of Ultivue, a spatial proteomics firm. Earlier, as SVP Finance and Operations at Invaio Sciences, he managed a global finance team during initial product commercialization and fundraising phases. His career also includes investment banking roles at Morgan Stanley and Bank of America Merrill Lynch. Seth received his MBA from Northwestern University’s Kellogg School of Management and his BSc in Biology from Duke University.
Seth Benson, CFO, Nuclera, remarked: “I am thrilled to join Nuclera at such an exhilarating phase for the company. The eProtein Discovery system addresses a significant challenge in protein production workflows and has the potential to profoundly influence drug discovery. I am eager to collaborate with Michael and the team to build upon the Company’s solid foundation and foster commercial growth.”
Dr. Michael Chen, CEO and co-founder of Nuclera, stated: “We are excited to welcome Seth to Nuclera at this crucial juncture in our journey. His financial leadership and strategic expertise in high-growth life sciences will be vital as we hasten the commercial launch of our eProtein Discovery system. I would also like to express gratitude to Jiahao for his invaluable contributions to Nuclera’s growth and achievements since co-founding the company in 2013. His efforts have been instrumental in establishing the company’s foundation and progress.”
